Insect control system

FIELD OF THE INVENTION

[0001] The present invention relates to methods for controlling insect populations using genetic techniques.

BACKGROUND OF THE INVENTION

[0002] Insects are responsible for widespread damage to crops world-wide with enormous concomitant economic consequences. To try to reduce insect-inflicted damage, resources have been devoted to the development and deployment of insecticides, which control insect populations by killing target insects. Although insecticides are in many cases effective, they are known to be toxic to life forms other than target insects, which has important environmental consequences. It would therefore be advantageous to develop inactive pro-insecticides which are converted into their active form predominantly in the target insect.

[0003] Attempts have been made to control insects by biological means. For example, methods currently employed to control the populations of certain members of the dipteran class include the release of sterile males.

[0004] For example, as set forth in U.S. Pat. No. 5,840,865, the Mediterranean fruit-fly (Medfly) Ceratitis capitata is a major agricultural pest for many fruit species that is geographically widespread in tropical and temperate regions. The Medfly has been introduced relatively recently into the New World, and appears to be spreading rapidly, threatening fruit producing areas in North America (Carey, J. R., Science 253: 1369 (1991)). Since the mid 1970's, the sterile insect technique has been used for Medfly eradication and control. This method relies on the decrease in or collapse of fly populations following releases of large numbers of sterile insects over infested areas, and offers an environmentally attractive alternative to massive spraying with insecticides (Knipling, E. F., Science 130: 902 (1959)).

[0005] Although the use of sterile male insects slows Medfly population growth and may lead to its temporary collapse, it does not lead to destruction of female insects, which are responsible for crop damage. Moreover, since the sterile males do not reproduce, the method requires repeated releases of sterile males into the environment. Recent improvements include the potential elimination of transgenic female in mass rearing environments using inducible terminator genes under the control of the antibiotic tetracycline (Heinrich and Scott, PNAS 97:8229-8232, 2000).

[0006] There therefore remains a need for a control technique for Medfly and other insects and other pests which can selectively destroy female or male insects but which is environmentally more acceptable than the mass spraying of toxic insecticides and does not require the large scale use of antibiotics for improved sterile techniques.

[0007] Furthermore, many human and veterinary health issues are associated with the spread of disease by insects. Examples include mosquitoes, tse-tse flies and the common housefly. Control of insect populations which endanger human or animal health is thus also desirable.

SUMMARY OF THE INVENTION

[0008] The present invention provides a method for controlling a population of target insects, comprising:

[0009] a) providing a gene comprising a coding sequence encoding one constituent of an enzyme/pro-drug system and a promoter capable of driving the coding sequence in the target insect in a sex-specific manner;

[0010] b) transforming at least part of the population of target insects with the gene, and allowing the transposable elements to spread within the target insect population; and

[0011] c) administering to the population of target insects the remaining constituent(s) of the enzyme/pro-drug system.

[0012] As used herein, a “population of target insects” refers to a group of insects, whether delimited along species or geographical lines, or both, which it is desired to be controlled. For example, a population of insects may refer to a given species of insect which infests a particular crop in a given geographical area. Alternatively, it may refer to all insects infesting any crop in a geographical area, or a given species without reference to any geographical limitation, or a population of insects which is responsible for a human or veterinary health problem, such as the spread of malaria. Target insects are the individual members of the population of insects.

[0013] “Insecticide” as used herein means any pesticide that is meant to control any target insect by targeting the insect cells. Insecticides which can be modified according to the invention to be pro-insecticides include but are not limited to imidacloprid and methamidophos.

[0014] “Pro-insecticide”, “pro-drug” and “pro-pesticide” are used interchangeably and as used herein mean any substantially inactive or substantially non-toxic substance in the absence of a converting enzyme, or mixture comprising such substance that can be converted to active or toxic substance by the action of an enzyme. Pro-insecticides can be specifically designed for the purpose or preferably designed by chemically modifying existing insecticides using, for example, methylation or acetylation as taught herein. The term “substantially” as used herein means “pro-insecticide”, “pro-drug” and “pro-pesticide”, which is at least 50%; 60%; 70%; 80; 90%; 95%; 98% and up to and including 100% inactive when compared to the active form.

[0015] “Enzyme” as used herein means a reaction catalyzing substance including but not limited to protein or polypeptide or a fragment of such protein or polypeptide. An “enxyme” as used herein catalyzes a reaction which converts a pro-insecticide or pro-drug to be an insecticide or drug, respectively. Examples of enzymes include but are not limited to oxidases, esterases, and amidases.

[0016] “Control” as used herein refers to the limitation, prevention or reduction of growth, i.e., by at least about 10% per generation, preferably at least about 50%, 80%, or even up to and including 100% of the insect population. Preferably, this is achieved by killing target insects. Advantageously, the population of insects is eliminated.

[0017] “Gene”, as used herein, refers to a nucleic acid sequence, usually DNA, which encodes a polypeptide or protein and additionally comprises the nucleic acid sequences required to transcribe the coding sequence in a suitable host cell. The nucleotide sequence encoding the polypeptide or protein is referred to herein as a “coding sequence” and the sequences required for regulation of sequence transcription are referred to as “control sequence”, such as “enhancer” or “promoter.”

[0018] The coding sequence encodes one constituent of an enzyme/pro-drug system. The constituent may be any one or more parts of the system, as long as it is not itself sufficient to produce or transform itself into the active drug from the pro-drug. Thus, the constituent is preferably an enzyme or a fragment of an enzyme which is responsible for pro-drug activation. Alternatively, it may be the pro-drug itself. The remaining constituent(s) of the enzyme/pro-drug system are administered separately, for example by spraying, thus killing the target insects which express the coding sequence according to the invention.

[0019] A feature of the present invention is that the promoter used to drive transcription of the coding sequence is functionally active in a sex-specific manner. This means that the coding sequence is expressed substantially only in one sex of the target insects, be it male or female. As used herein, “substantially only” refers to a selectivity for a given sex in the ratio of at least about 70:30, 80:20, 90:10 or preferably 100:0. The gene which is used to transform the insects is preferably used to transform male target insects. Male transformation is especially preferred when a promoter which is used to drive the coding sequence is functional only in female target insects. This allows the selective destruction of female insects, while maintaining a population of male insects which are able to pass on the gene comprising the coding sequence whilst remaining unaffected by the pro-drug. This is approach is highly advantageous where the female is responsible for spreading damage or disease.

[0020] In cases where the male is responsible for spreading damage or disease, the technique may be reversed, such that a coding sequence only functional in male insects is spread by carrier females.

[0021] The invention furthermore provides an insect of a given sex, which insect has been transformed with a gene comprising a coding sequence encoding one constituent of an enzyme/pro-drug system and a regulatory region, preferably promoter, operably linked and capable of driving the coding sequence substantially only in insects of the opposite sex. After selection in mass rearing conditions the surviving insects can be optionally irradicated for the use of sterile insect techniques.

[0022] In a further aspect, the invention provides a vector which is capable of transforming a target insect cell, which vector comprises a gene comprising a coding sequence encoding one constituent of an enzyme/pro-drug system and a promoter capable of driving the coding sequence in target insects in a sex-specific manner.

BRIEF DESCRIPTION OF THE FIGURES

[0023]
FIG. 1. Schematic representation of the YP/GFP transposon. Hsp70P is a promoter and Hsp70T is the terminator sequence of the D. melanogaster Hsp70 gene (Loukeris et al. 1995, Science 270, 2002-2005). C. c. white means the wild-type white-cDNA of Ceratitis capitata (Zwiebel et al. 1995, Science 270, 2005, Loukeris et al. 1995, Science 270, 2002-2005). GFP is the S65T mutant of the Aequorea victoria gene encoding Green Fluorescent Protein (Heim et al. Nature 373:663-664, 1995). YP1P is the fat body promoter/enhancer of the gene encoding Yolk Protein 1 of Drosophila melanogaster. The XhoII BamHI fragment containing the YP1 promoter/enhancer (from bases −362 to +54, Genbank Accession Number X01524) was obtained by PCR from Drosophila (strain yw) DNA. The transposon is cloned in plasmid vector pTZ18-19 (Pharmacia).

[0024]
FIG. 2. Expression of GFP flies under the control of the Drosophila YP promoter in Drosophila melanogaster. (A) Homozygous transformed male; (B) heterozygous transformed female; (C) homozygous transformed female; (D) non-transformed female. The same field was photographed for epifluorescence (top) and for epifluorescence with faint incident light (bottom), to demonstrate non-fluorescing flies.

[0025]
FIG. 3. Female-specific expression of GFP in Medflies under the control of the Drosophila YP promoter. A transformed female is shown on the left. A transformed male is shown on the right. Top: Epifluorescence. Bottom: Incident light.

[0026]
FIG. 4. Western-blot analysis of YP-promoter -directed expression of GFP in Drosophila melanogaster flies. The number identifying the transformed line is indicated at the top as C meaning a control, non-transformed fly, 42.1, 19.3, 21.2. F indicates female fly and M indicates male fly. Groups of ten flies (2-5 day old) were homogenized in 20 mM Tris.HCl pH 8.0 containing 10 mM EDTA, 5 mM β-mercaptoethanol and 30 mM NaCl. A supernatant from centrifugation with 14000×g was subjected to SDS-PAGE and blotted onto a nitrocellulose filter. An anti-GFP monoclonal antibody (CLONTECH Laboratories, Inc., Palo Alto, Calif.) and a commercial secondary antibody coupled to horseradish peroxidase were used for detection. The high molecular weight fragments are due to background.

[0027]
FIG. 5. Sensitivity of D. melanogaster (strain yw) to 5-FU. The yw strain is used routinely as recipient for generation of transgenic lines. Flies were reared in stadard Drosophila food supplemented with 5-FU at the indicated concentrations of 0 mM, 5 mM, 10 mM, 20 mM, 30 mM, 50 mM 5-FU. The x-axis represents time in days and the y-axis represents the number of flies. The data points represent the number of surviving flies.

[0028]
FIG. 6. Dose-dependent lethality of D. melanogaster to 5-FU. The x-axis represents 5-FU concentration in mM and the y-axis represents the number of flies. Strain yw flies that were used in the above described transformation experiment were reared in standard Drosophila food supplemented with 5-FU at the indicated concentrations and viable flies were determined after 9 days. Each data point represents the mean±standard deviation of three separate experiments, each with 100 flies.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The present invention is applicable to control any target insect population, comprising any target insects, whether the population is homogenous or heterogeneous. For example, insects which are controlled using the present invention include but are not limited to Bactrocera oleae (olive fly) which affects olive crops; Bactrocera orientalis (oriental fruit fly) which affects many fruit crops; Heliothis armigera (cotton bollworm) which affects cotton; Trichoplusa ni (cabbage looper) which affects cabbages; Manduca sexta (tobacco hornworm) which affects tobacco; Lobesia botrana (grapevine moth) which affects grapes; Anopheles gambiae (mosquito) which carries malaria; Aedes aegypti (yellow fever mosquito) which causes yellow fever; Glossina morsitans (tse-tse fly) which carries African trypanosomiasis (sleeping sickness); Simulium sp. (black fly) which causes onchocerciacis (river blindness); Phlebotomus sp. (sand fly) which causes visceral leishmaniasis (kala-azar); Musca domestica (house fly) which spreads many bacterial infections. In preferred embodiment, the present invention is used in insect populations which include or consist of the Mediterranean fruitfly, C. capitata (Medfly).

[0030] Pro-Drug Systems Useful According to the Present Invention

[0031] Pro-drug-converting enzyme genes, also known as “suicide” genes have been used to subsequently activate cytotoxic drugs selectively in transfected tumor cells. Enzyme/pro-drug systems are known in the art. A pro-drug is a drug, often a potentially toxic drug, which is selectively activated, i.e. rendered toxic, by the action of an enzyme. Enzyme/pro-drug systems rely on the delivery of an enzyme to target cells or organisms, before administration of the pro-drug. Only target cells or organisms which express the enzyme will be affected by the pro-drug. One common enzyme/pro-drug system is the 5-fluorouracil/cytosine deaminase system, in which the non-toxic precursor 5-fluorocytosine (5-FC) is converted to the cytotoxic drug 5-fluorouracil (5-FU) by the action of cytosine deaminase (see Austin & Huber, (1993) Mol. Pharmacol. 43:380-387).

[0032] In one embodiment, enzymes that can be used for converting a pro-pesticide into an active pesticide, such as esterases, amidases and mixed-function oxidases which are also called P450, can be characterized and cloned from a variety of organisms, including eubacteria, archaebacteria and eukaria. A typical strategy for utilizing such an enzyme, e.g. metabolizing a specific pro-pesticide, would entail sreening of organisms for presence of the enzymatic activity. A collection of organisms can be used for this purpose, such as a collection of cultured soil bacteria, a collection of insect tissues or cells or a collection of plant tissues or cells.

[0033] Screening can be performed, for example, by incubating the pro-pesticide with an extract from tissues or from bacteria. In the case of mixed function oxidases that are localized in microsomes from eukaryotic tissues, a microsomal fraction can be used as source of the activity. A microsomal fraction can be isolated by routine subcellular fractionation procedures. High speed supernatants of cell extracts can be used for other soluble enzymes. Determination of enzymatic activity can be performed by detecting the reaction product(s) by standard chemical analytical technologies well know to one skilled in art. For example, reaction product(s) can be separated using gas chromatography (GC). Mass spectrometry coupled to GC (GCMS) can be used to confirm the structure of the compounds.

[0034] Once the enzyme activity is determined, the gene encoding the activating enzyme can be cloned by using a variety of different cloning methods well know in art. For example, a nucleic acid library of the organism is generated using standard recombinant DNA technology. A genomic library for bacterial genes or a cDNA library for eukaryote genes can then be screened using standard methodology.

[0035] In one embodiment, hybridization with nucleic acid probes from a related gene, e.g. a cloned sterase or P450 gene from an evolutionarily related organism, is used. Alternatively, screening can be done by complementation. In the latter approach, an expression library, i.e. a library construed in a commercially available expression plasmid or viral vector, is used to transfect cells that do not normally express the enzymatic activity, and the clone containing the activating gene is isolated by screening individual colonies of the library for expression of enzymatic activity. A newly identified gene can then be cloned into vectors useful according to the invention, describe below.

[0036] Pro-drugs, as well as being inactive in organisms or cells that cannot convert them, may also have other advantages, such as improved lipid solubility and/or chemical stability.

[0037] Pro-insecticides or pro-drug toxins that have been designed to be convertible only in certain insects, are known in the art and have been prepared, for example, by selective derivatisation of the final toxin, especially in the case of organophosphates and carbamates. Examples include precursors of acetylcholinesterase inhibitors, such as parathion and profenofos, which are oxidised into active insecticides by enzymes of the cytochrome P-450 family. However, application of proinsecticides to insect populations only kills the insects which naturally express the enzyme. To render insect pests which do not naturally express the converting enzyme susceptible requires transfer of the gene encoding the converting enzyme into the host and a means of transfer of the gene in an environmentally acceptable manner within the target insect population

[0038] In one embodiment, the converting enzyme coding sequence encodes the esterase enzyme which converts DPX-JW062 into its active metabolite as disclosed by Wing et al. incorporated herein by reference (Wing et al. Arch Insect Biochem Physiol 37:91-103, 1998). The pro-insecticide is, in this aspect of the invention, DPX-JW062. DPX-JW062 is an oxadiazine compound bioconverted in lepdoptera into a potent toxin which blocks voltage-gated sodium channels. DPX-JW062 has low activity/toxicity in other organisms. Consequently, the expression of the lepdoptera converting enzyme in other insects will make the target insects susceptible to DPX-JW062 induced toxicity.

[0039] Alternatively, the coding sequence encodes an enzyme of the cytochrome P-450 family. Although most insects possess cytochrome P-450 family enzymes, the efficiency of bioconversion of proinsecticides converted by such enzymes may be increased by transforming the insect with a more efficient and/or overexpressed enzyme, allowing a decrease in the effective dose of the proinsecticide. Suitable proinsecticides in this aspect of the invention include organophosphates and carbamates. For example, the proinsecticide may be an acetylcholinesterase inhibitor such as parathion and profenofos. The cloning and expression of the orphid cytochrome P-450 enzymes responsible for the conversion of parathion and profenofos to them and we found would allow a broadening of the susceptible [ ] range through the expression in otherwise resistant insect species.

[0040] Generally, genes useful in the practice of the invention, as well as vectors encoding them, may be prepared according to standard approaches used in molecular biology. See, for example, Sambrook et al., Molecular Cloning, A Laboratory Manual (1989) and Ausubel et al. Short Protocols in Molecular Biology (1999) 4th Ed, John Wiley & Sons, Inc.

[0041] A gene encoding cytosine deaminase (CD) is one example of the pro-drug-converting enzymes. The bacterial enzyme cytosine deaminase (CD; EC 3.5.4.1) encoded by cod A is present in many bacteria and fungi but is absent in higher plants and animals. CD catalyzes the deamination of cytosine to uracil. Microorganisms that express the CD gene convert through a similar mechanism the non-toxic 5-fluorocytosine (5-FC) into the 5-fluorouracil (5-FU), a highly toxic metabolite that is lethal to the cell. Since higher organisms do not usually express cytosine deaminase they do not ordinarily metabolize cytosine to uracil. Moreover they do not deaminate 5-FC. The 5-FC is non-toxic to eukaryotes at concentrations that result in strong antimicrobial activity. However, 5-FU has potent cytotoxic effects on eukaryotic cells and is widely used as a chemotherapeutic agent in cancer treatment. The 5-FU is metabolized to 5-fluorouridine 5′-triphosphate and 5-fluoro-2′-deoxyuridine 5′-monophosphate, inhibiting both RNA and DNA synthesis and resulting in cell death. Thus, eukaryotic cells engineered to express CD should convert 5-FC to 5-FU and be selectively sensitive to 5-FC compared to native, unmodified cells. This was first demonstrated using human colorectal carcinoma cells transfected with a construct expressing bacterial CD. The transfected colorectal carcinoma cells are about 600-fold more sensitive to 5-FC than untransfected cells (Austin and Huber, 1993, Molec. Pharmacol. 43: 380-387).

[0042] According to a further embodiment, the pro-drug is p-hydroxyaniline mustard glucuronide, which is converted to the toxin p-hydroxyaniline mustard by the converting enzyme β-glucuronidase, which must be located in the extracellular space (Cheng et al., Biochem. Pharmacol. 58:325-328, 1999). Preferably, therefore, the coding sequence encodes E. coli β-glucuronidase.

[0043] Female-Specific Regulatory Regions According to the Invention

[0044] A “regulatory region” which regulates a coding sequence includes one or more of promoters or one or more enhancers.

[0045] A “promoter” is herein defined as a nucleotide sequence which initiates transcription of a gene which it is operatively associated with. A “promoter” and/or “enhancer” is found on a nucleic acid fragment, which may be of any size, as long as it confers the stated activity when operatively associated with a gene or a coding sequence of interest. The fragment may be, e.g. 5 kilo base pairs (kb=5000 base pairs); 1 kb; 500 nucleotides (nt); 200 nt; 100 nt; or even as small as 10-20 nt.

[0046] Yolk protein genes are highly conserved (Sappington and Raikhel, 1995, Insect Biochem Mol Biol 28, 277-300). Systems based on a number of drosophila yolk protein genes have been characterized, (Ronaldson and Bownes, 1995, Genet Res 66:9-17) and used to effect female specific heterologous gene expression (see, Heinrich and Scott, 2000, PNAS 97:8229-8232; Thomas et al., 2000, Science 287:2474-2476). Yolk protein genes have also been characterized for the Medfly (Rina and Savakin, 1991, Genetics 127:769-780). The conserved nature of yolk protein genes indicates that regulatory elements driving heterologous genes in female insects can be isolated and characterized using standard genetic approach. Thus sex-specific promoters suitable for driving a coding sequence as set forth above are available in the art. In a preferred embodiment, vitellogenin genes encoding yolk proteins may be used as a source of suitable promoters. In the case where the target insects are Medfly (C. capitata), the VG1 and VG2 promoters may be used as disclosed in Rina and Savakis, Genetics 127:769-80, 1991 herein incorporated by reference.

[0047] The Drosophila Yp-enhancer. The Yolk protein (Yp) genes in Drosophila melanogaster follow a strict tissue- sex- and temporal-specific expression pattern, being transcribed only in adult female fat body and ovarian follicle cells. A fat body enhancer (FBE) located 196 bp upstream of the Yp1 cap site is sufficient to determine the sex-, stage- and fat body-specific expression of both yp1 and yp2 genes as described by Garabedian et al. Cell 45:859-867, 1985, herein incorporated by reference. More recently, a simple enhancer (33 bp) within the FBE has been postulated to be involved in the regulation of the yp gene expression. This female- and fat body-specific enhancer consists of two enhancer elements (o and r). One element (22 bp) contains two protein binding sites, the dsx A and an overlapping bzip1, that binds the DmC/EBP (slbo) protein, a member of the bZIP family of transcriptional activators. The other element is an 11 bp binding site for an unknown protein (An and Wensink, 1995, EMBO J. 14:1221-1230).

[0048] Vectors and Transformation According to the Invention

[0049] The transformation of target insects may be performed using any suitable technique for preparing transgenic insects. Currently, there are several art recognized techniques such as DNA transfection using transgesons, the use of viral vectors, and the use of episomal vectors which are transmitted through germ cells. Preferably, the transformation is carried out using a suitable vector. The invention thus provides a vector which is capable of transforming a target insect cell, which vector comprises a gene comprising a coding sequence encoding one constituent of an enzyme/pro-drug system and a promoter capable of driving the coding sequence in target insects in a sex-specific manner.

[0050] Preferably, the vector is a transposon or transposable element. The invention accordingly provides a method as set forth above. wherein the transformation step comprises the steps of:

[0051] (a) providing transposon either as a transposable element which encodes a transposase protein which is active in the target insects; an RNA encoding a transposase or purified transposase protein.

[0052] (b) modifying the transposable element by inserting reglatory elements and the gene encoding the activity enzyme; and

[0053] (c) transforming the target insects with the modified transposable element in the presence of transposase activity.

[0054] Transposons are genetic elements which are capable of “jumping” or transposing from one position to another within the genome of a species. They are widely distributed amongst animals, including insects. Transposons are active within their host species due to the activity of a transposase protein encoded by the elements themselves. Advances in the understanding of the mechanisms of transposition have resulted in the development of genetic tools based on transposons which can be used for gene transfer.

[0055] Any transposable element active in the desired target insect may be used. Preferably, however, the transposable element is selected from the Tet/Mariner superfamily of transposons consisting essentially of Minos, mariner, Hermes and piggyBac.

[0056] Minos is a transposable element which is active in Medfly. It is described in U.S. Pat. No. 5,840,865, which is incorporated herein by reference in its entirety. The use of Minos to transform insects is described in the foregoing US patent.

[0057] Mariner is a transposon originally isolated from Drosophila, but since discovered in several invertebrate and vertebrate species. The use of mariner to transform organisms is described in International patent application WO99/09817.

[0058] Hermes is derived from the common housefly. Its use in creating transgenic insects is described in U.S. Pat. No. 5,614,398, incorporated herein by reference in its entirety.

[0059] PiggyBac is a transposon derived from the baculovirus host Trichplusia ni. Its use for germ-line transformation of Medfly has been described by Handler et al., (1998) PNAS (USA) 95:7520-5.

[0060] According to the present invention, insects are generated which can be released into wild-type populations of insects. The transgenic insects of the invention will consequently interbreed with the wild-type populations to produce target insects which are susceptible to a proinsecticide. The invention thus relates to an insect of a given sex, which insect has been transformed with a gene comprising a coding sequence encoding one constituent of an enzyme/pro-drug system and a promoter capable of driving the coding sequence substantially only in insects of the opposite sex. Preferably, the insect is a male insect. Preferably the insect can be mass reared. More preferably, the insect is a Medfly.

[0061] Designing Pro-Pesticides from Pre-Existing Pesticides According to the Invention

[0062] To create non-toxic pro-insecticides, currently available insecticides can be rendered inactive by derivatizing a chemical group that is required for biological activity. Such groups include, but are not limited to, amino or imino groups. Derivatization can be performed by, for example, methylation or acetylation.

[0063] Metabolic activation is an enzymatic process in the target species that converts the pesticide to a biologically more active structure. Thus, weak inhibitors or noninhibitors may be accidentally changed into products of lethal toxicity by systems designed to degrade xenobiotic compounds (p. 129 in Insecticide Mode of Action ed. Joel R. Coats, Academic Press, 1982).

[0064] In the general field of phosphate insecticides, the most common activation process mediated by mixed-function oxidase is the P→S to P→O conversion, e.g. parathion to paraoxon. (Nakatsogawa and Morelli, 1976; Ero, 1974; Fukuto, 1978).

[0065] In one embodiment of the invention, acephate-methamidophos propesticide-pesticide system can be used. Methamidophos (O, S-dimethyl phosphoramidothicate, C2H8NO2PS) was introduced in 1969 by Chevron Chemical and Bayer. It is a highly active, systemic, residual organophosphate insecticide/acaricide with contact and stomach action. Methamidophos is a potent acetylcholinesterase (AchE) inhibitor. It is effective against chewing and sucking insects and is used to control aphids, flea beetles, worms, whiteflies, thrips, cabbage loopers, Colorado potato beetles, potato tubeworms, armyworms, mites, leafhoppers, and many others. Toxicity of methamidophos has been determined as acute oral LD50 values of 21 and 16 mg/kg body weight for male and female rats respectively.

[0066] Acephate is a N-acetyl derivative of methamidophos (O, S-dimethyl acetylphosphoramidothicate, C9H10NO3PS) which was introduced by Chevron Chemical as a second-generation improvement of methamidophos. It is used for control of a wide range of biting and sucking insects, especially aphids, including resistant species, in fruit, vegetables (e.g. potatoes and sugar beets), vine, and hop cultivation and in horticulture (e.g. on roses and chrysanthemums grown outdoors). Acephate and its primary metabolite, methamidophos, are toxic to Heliothis spp. that are considered resistant to other organophosphate insecticides. Toxicity of Acephate has been determined as acute oral LD50 Value A 945 and 866 mg/kg for male and female rats respectively (45 to 54-fold less toxic than its metabolite methamidophos).

[0067] Acephate itself is not an AchE inhibitor; its conversion to methamidophos, which is an inhibitor, requires an enzyme-mediated cleavage of the carbonyl-N bond. Nearly all living systems contain amidases that cleave simple aliphatic amides. However, acephate is not a simple amide and some nonspecific amidases may find it a poor substrate. Methamidophos has been observed as the principle metabolite of acephate in bean, cabbage and tomato seedlings (Tucker, 1972, Report, Chevron Chemical Company, Richmont, Calif.). The cleavage of the carbonyl-N bond is not a nonspecific process, as is indicated by findings that activity of the activating amidases is highly sensitive to variations in the acephate structure.

[0068] There appears to be a direct relation of the activation reaction and toxicity in target insects. In the tobacco budworm Heliothis virescens acephate and methamidophos show comparable activity. A small amount of methamidophos was observed in the budworm larvae within 2 hours of a topical acephate application. However, in the adult boll weevil Anthonomus granids Boheman methamidophos is 75-fold more toxic than acephate despite rapid absorbsion of both compounds. No metabolism of acephate to methamidophos was observed in the boll weevil, a fact consistent with its low toxicity (Bull, 1979, J. Agric. Food Chem. 27:268).

[0069] Many living organisms possess one or more amidases that cleave a significant fraction of applied acephate to methamidophos. Animals such as the rat (Tucker, 1976) and the female white mouse (Kao and Fukuto, 1977) also convert a significant amount of acephate or its analogs to methamidophos. In their study on the propionyl and hexanoyl analogs, Kao and Fukuto were able to relate the toxicity directly to the amount of activation. This strongly suggests that unconverted acephate is essentially nontoxic.

[0070] Thus the combination of a gene encoding an amidan enzyme capable of converting acephate to its active form methamidophos will render a [ ] insect susceptible to applications of the previously non-toxic acephate.

[0071] It has also been reported that the toxicity of acephate analogs to the house fly is consistent with the amount of metabolically formed methamidophos; the propionyl analog generates substantially more methamidophos in this specis and is 35-fold more toxic (Kao and Fukuto, 1977, Pestc. Biochem. Physiol. 7:83).

[0072] In another embodiment of the invention, Imidacloprid (1-[8-chloro-3-pyridinyl)methyl]-N-nitro-2-imidazolidinimine, C9H10CIN5O2) and N-Me-imidacloprid can be used as a pro-pesticide system.

[0073] Imidacloprid is a systemic, chloro-nicotinyl insecticide for the control of sucking insects including rice hoppers, aphids, thrips, whiteflies, termites, turf insects, soil insects and some beetles. It is most commonly used on rice, cereal, maize, potatoes, vegetables, sugar beets, fruit, cotton, hops and turf, and is especially systemic when used as a seed or soil treatment. The chemical works by interfering with the nicotinergic acetylcholine receptor (nAcR) which is more abundant in insects than in warm-blooded animals. It is effective on contact and via stomach action. (Kidd, H. and James, D. R., Eds. The Agrochemicals Handbook, Third Edition. Royal Society of Chemistry Information Services, Cambridge, UK, 1991 (As Updated). 10-2). Toxicity for imidacloprid has been determined as acute oral LD50 in rats is 450 mg/kg body weight.

[0074] N-Me-imidacloprid is an imidacloprid pro-insecticide. Introduction of a methyl group at the 3 position of the imidazole ring imidacloprid decreases binding affinity to nAcR 100-fold. However, N-Me-imidacloprid is as potent as imidacloprid in the housefly. N-Me-imidacloprid can be converted to imidacloprid by an in vitro mixed function oxidase system (Yamamoto et al. 1998, Arch. Insect Biochem. Physiol. 37:24). The compound is not commercially available. Currently, no toxicity data are available for N-Me-imidacloprid.

[0075] The conversion of N-Me-imidacloprid to imidacloprid in the housefy indicates the presence of enzymes capable of effecting pro-pesticide conversion. See Magee (1982) in Structure-Act In Vivo relationships in phosphoramidates, Chp 5, Insecticide made action Academic Press.

[0076] The resulting derivative (pro-pesticide) can be metabolized to the active pesticide by enzymes or “activating enzymes” that occur or are transfected into target insects. Several activating enzymes can be used including but not limited to oxidases (P450), esterases and amidases.

[0077] In summary a gene encoding an activating enzyme that converts a pro-pesticide into an active pesticide is introduced into the genome of pest species that do not normally produce the activating enzyme or have low levels of activating enzyme. The sex specific expression of the activating enzyme in the target pest population enhances the spread of the gene in the local pest population when combined with the application of the pro-pesticide systemically or non-systemically. In the preferred embodiment this will result in the selective elimination of the female pest population. Recombinant surviving males will then breed driving the activaiton gene through the local population resulting after cycles of application of proinsecticide in the reduction or elimination of female pests and hence reduction or elimination of a viable local pest population.

[0078] Designing a pro-pesticide which is based on a registered pesticide such as imidacloprid has an important economical advantage over introducing a novel pro-pesticide: The known toxicology of the pesticide is utilized instead of establishing the extensive toxicology analysis of a novel compound which decreases time to market and costs for toxicology analysis.

EXAMPLES

[0079] Example 1. Preparation of a Construct Encoding E. Coli Cytosine Deaminase

[0080] Using standard methods, a genetic construct is prepared bearing the C. capitata VG1 promoter operably linked to a cDNA encoding E. coli cytosine deaminase. The cytosine deaminase gene, when introduced into insect cells, confers sensitivity to the pro-drug 5-FC.

[0081] The construct is inserted into the Minos transposon using conventional techniques and, in addition, those described in U.S. Pat. No. 5,840,865. The modified transposon is then used to transform Medfly according to standard transgenesis procedures.

[0082] Transgenic flies carrying the modified transposon are bred to create transgenic strains that express the cytosine deaminase enzyme. Characterisation for cytosine deaminase activity shows that the enzyme is expressed at a high level selectively in females. Moreover, cytosine deaminase expression is correlated with susceptibility to the pro-drug 5-FC administered in food to the flies.

[0083] A highly susceptible strain is bred and male flies isolated. Introduction of male flies into a population of non-transgenic flies results in rapid transfer of the transgene. Female flies which are born inheriting the transgene are susceptible to 5-FC, whilst male files remain resistant.

[0084] Example 2. Preparation of the Yp-CDASE Construct

[0085] Two specific oligonucleotides which correspond to the published sequence of the CD gene (Austin and Huber, 1993, Molec. Pharmacol. 43:380-387) were used in polymerase chain reaction (PCR). The first oligonucleotide was used to introduce a more closely matching Kozak consensus start codon “ATG” in the place of “GTC” in the published sequence. Oligonucleotide 5′-CGGGATCCACCATGTCGAATAACGCTTTAC-3′ corresponds to the 5′ end of the CD sequence but changes the start codon from GTG to ATG, more closely matches the Kozak consensus sequence (Kozak, 1986, Cell 44: 283-292) The second oligonucleotide introduced BamHI-restriction site starting 9 bp upstream from the ATG. Oligonucleotide 5′-GCTCTAGATCAACGTTTGTAATCGATGGC-3′ corresponds to the 3′ end of the CD sequence and contains an Xba I restriction site. A 1.3 kb DNA fragment of the modified CD gene was amplified by PCR using template DNA from an XL1 blue E. coli strain. The PCR product was cloned into a pGEM-T Easy vector (Promega, Madison, Wis.).

[0086] As a first step in the construction of a female-specific CD expression vector, a Not I fragment containing the CD gene was cloned into pCasper-hs. Vector pCasper-hs (Thummel and Pirrotta, 1992, Technical Notes. D.I.S. 71; 150) is a P element based transformation vector containing a Hsp70 promoter/terminator construct that can be used for expressing open reading frames under heat shock control. In the second step, the resulting plasmid, pCasper-hs-CD, was cut with XhoI/Bgll I and a XhoII/BamHI fragment containing the YP1 promoter/enhancer was used to replace the Hsp70 promoter. The resulting plasmid vector pCasper-YP-CD was used to transform Drosophila.

[0087] Example 3. Female-Specific Expression of Green Fluorescent Protein (GFP) Using Drosophila Yp-enhancer

[0088] Ten transgenic Drosophila lines were generated using Minos-mediated germ line transformation, each carrying a single copy of a transposon (MiYP/GFP-w) that contains the Aequorea victoria gene for the GFP driven by the Drosophila melanogaster Yp1 fat body promoter/emhancer (FIG. 1). In all lines, GFP fluorescence is detectable in the fat body of adult females, is dose-dependent, but it is undetectable in aduit males (FIG. 2). 15 medfly transgenic lines have been generated using the same transposon. FIG. 2 shows female-specific expression of GFP driven by the Drosophila YP promoter in one of these medfly lines.

[0089] Sex-specific expression of GFP protein in some of these transgenic lines has also been documented by Western blot analysis using a commercially available monoclonal anti-GFP antibody (FIG. 4).

[0090] Example 3. Transformation of Drosophila.

[0091] Transformation was performed using previously described methodology (Rubin and Spradling, 1982, Science 218, 348-353). Transformants were detected by screening the G1 progeny of the injected flies for expression of the dominant white marker present in pCasper-YP-CD.

[0092] Example 4. Detection of Female-Specific Expression of CDASE by Detection of CD Enzymatic Activity

[0093] CD enzyme activity was determined both in transformed flies, females and males, and in a yw-strain which lacks CD expression. The ability of flies to deaminate 5-FC to 5-FU was assayed spectrophotometrically as described previously (Austin and Huber1993, Molec. Pharmacol. 43: 380-387). Briefly, frozen flies were homogenized in homogenazation buffer (100 mM Tris-Cl, pH 7.4, 1 mM ethylenediaminetetraacetic acid [EDTA], 5 mM β-mercaptoethanol and 0.5 mM PMSF) using an Ultra-Turrex homogenizer. The homogenate was centrifuged at 14,000 g for 30 min and the supernatant was used for the assay. CD activity was measured in a1-ml assay mixture containing 50 mM Tris-Cl, pH 7.3, 50 μl of supernatant and 0.5 mM cytosine or 5-FC. Decreases in absorbance at 285 nm were measured over time. Product was estimated by using a molar extinction coefficient of 1.038×10−3 M−1cm−1 for cytosine to uracil and 1.96 mM−1 cm−1 for 5-FC to 5-FU.

[0094] Example 5. Detection of Female-Specific Expression of CDASE by Detection of CD Protein

[0095] Whole fly extracts that were prepared for CD enzymatic assays described above, were also analyzed on SDS-PAGE. A fragment migrating with an apparent molecular weight of approximately 52,000 was detected in extracts prepared from transformed female flies; this fragment was not detectable in non-transformed flies or in transformed male flies. The identity of the 52 kD band was confirmed with Western blot analysis using a polyclonal antibody for CD.

[0096] Example 6. Determination of the Female Toxicity by Feeding Variable Concentrations of Active Compound

[0097] To evaluate the effects of 5-FU on a D. melanogaster yw strain, flies were raised first on medium containing 5-FU. Groups of 25 flies were cultured on food containing various concentrations of the drug. Four vials of each concentration of the drug were used for each experiment and three experiments were performed. The surviving flies per vial were counted over a period of time. FIG. 5. shows survival rates over time for several concentrations of the drug; FIG. 6. shows dose-response for survival at nine days. 5-FU treatment caused efficient killing of flies in a concentration range 30-50 mM within 9 days. No eggs were laid on food containing more than 20 mM of 5-FU.

[0098] The effects of the pro-drug 5-FC on non-transformed adult flies were determined in a similar way. Pro-drug treatment of non-transformed flies resulted in substantially no reduction if fly viability.

[0099] Example 7. Determination of Female Toxicity by Using Variable Concentrations of Pro-Drug

[0100] The effect of the pro-drug 5-FC on CD transformed flies was determined by raising the flies on food containing various concentrations of 5-FC. Female CD files showed a substantial reduction in viability with increasing 5-FC when compared with male CD files.

OTHER EMBODIMENTS

[0101] Other embodiments will be evident to those of skill in the art. It should be understood that the foregoing detailed description is provided for clarity only and is merely exemplary. The spirit and scope of the present invention are not limited to the above examples, but are encompassed by the following claims.

Number	Date	Country	Kind
9918536.5	Aug 1999	GB
9918540.7	Aug 1999	GB

Insect control system

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Priority Claims (2)

Provisional Applications (1)